PURPOSE: Several randomized, controlled trials (RCTs) have tested strategies to prevent sexual acquisition of HIV infection, but their quality has been variable. We aimed to identify, describe, and evaluate the quality of RCTs studying biomedical interventions to prevent HIV acquisition by sexual transmission. METHOD: We conducted a systematic review to identify all RCTs evaluating the efficacy of biomedical HIV prevention interventions. We assessed seven generic and content-specific quality components important in HIV prevention trials, factors influencing study power, co-interventions provided, and trial ethics. RESULTS: We identified 26 eligible RCTs. The median number of quality components judged to be in adequate or unclear was 3 (range 1-4) in 1992-1998, 3 (range 1-4) in 1999-2003, and 0 (range0-2) in 2004-2008 (p < .001). Common problems that may have biased results included low retention (median 84%), poor adherence to interventions requiring on going use (median < or =78%), and lower HIV incidence than expected a priori (in 8 of 11 trials where evaluable). CONCLUSION: Reporting of trials of biomedical HIV prevention interventions has improved over time. However, quality improvement is needed in several key areas that influence study power, including participant retention, adherence to interventions, and estimation of expected HIV incidence.
PURPOSE: Several randomized, controlled trials (RCTs) have tested strategies to prevent sexual acquisition of HIV infection, but their quality has been variable. We aimed to identify, describe, and evaluate the quality of RCTs studying biomedical interventions to prevent HIV acquisition by sexual transmission. METHOD: We conducted a systematic review to identify all RCTs evaluating the efficacy of biomedical HIV prevention interventions. We assessed seven generic and content-specific quality components important in HIV prevention trials, factors influencing study power, co-interventions provided, and trial ethics. RESULTS: We identified 26 eligible RCTs. The median number of quality components judged to be in adequate or unclear was 3 (range 1-4) in 1992-1998, 3 (range 1-4) in 1999-2003, and 0 (range0-2) in 2004-2008 (p < .001). Common problems that may have biased results included low retention (median 84%), poor adherence to interventions requiring on going use (median < or =78%), and lower HIV incidence than expected a priori (in 8 of 11 trials where evaluable). CONCLUSION: Reporting of trials of biomedical HIV prevention interventions has improved over time. However, quality improvement is needed in several key areas that influence study power, including participant retention, adherence to interventions, and estimation of expected HIV incidence.
Authors: K Fonck; R Kaul; J Kimani; F Keli; K S MacDonald; A R Ronald; F A Plummer; P Kirui; J J Bwayo; E N Ngugi; S Moses; M Temmerman Journal: Int J STD AIDS Date: 2000-12 Impact factor: 1.359
Authors: Elizabeth G Raymond; Douglas Taylor; Willard Cates; Elizabeth E Tolley; David Borasky; Aida Cancel; Benoit Masse; Elizabeth A Bukusi; Brooke R Johnson Journal: Sex Transm Dis Date: 2007-12 Impact factor: 2.830
Authors: Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya Journal: J Infect Dis Date: 2006-11-03 Impact factor: 5.226
Authors: A Kamali; M Quigley; J Nakiyingi; J Kinsman; J Kengeya-Kayondo; R Gopal; A Ojwiya; P Hughes; L M Carpenter; J Whitworth Journal: Lancet Date: 2003-02-22 Impact factor: 79.321
Authors: J Kreiss; E Ngugi; K Holmes; J Ndinya-Achola; P Waiyaki; P L Roberts; I Ruminjo; R Sajabi; J Kimata; T R Fleming Journal: JAMA Date: 1992 Jul 22-29 Impact factor: 56.272
Authors: Linnet Masese; Jared M Baeten; Barbra A Richardson; Elizabeth Bukusi; Grace John-Stewart; Susan M Graham; Juma Shafi; James Kiarie; Julie Overbaugh; R Scott McClelland Journal: AIDS Date: 2015-06-01 Impact factor: 4.177
Authors: Sharmistha Mishra; Marie-Claude Boily; Sheree Schwartz; Chris Beyrer; James F Blanchard; Stephen Moses; Delivette Castor; Nancy Phaswana-Mafuya; Peter Vickerman; Fatou Drame; Michel Alary; Stefan D Baral Journal: Ann Epidemiol Date: 2016-06-15 Impact factor: 3.797
Authors: T Kiriazova; D M Cheng; S M Coleman; E Blokhina; E Krupitsky; M C Lira; C Bridden; A Raj; J H Samet Journal: HIV Clin Trials Date: 2014 May-Jun
Authors: Lawrence Mbuagbaw; Amy Slogrove; Jacqueline Sas; John Kunda; Frederick Morfaw; Jackson Mukonzo; Lehana Thabane Journal: Pan Afr Med J Date: 2014-09-19
Authors: Kristin M Wall; William Kilembe; Mubiana Inambao; Yi No Chen; Mwaka Mchoongo; Linda Kimaru; Yuna Tiffany Hammond; Tyronza Sharkey; Kalonde Malama; T Roice Fulton; Alex Tran; Hanzunga Halumamba; Sarah Anderson; Nishant Kishore; Shawn Sarwar; Trisha Finnegan; David Mark; Susan A Allen Journal: Global Health Date: 2015-06-27 Impact factor: 4.185